Efficacy of simple bladder hydrodistention in treatment for female refractory overactive bladder
SHI Xiaozhi1* QIAO Ximin2 XU Xiaofeng2 DU Quan2* LIU Guoxiong2
1.The Second Clinical Medicine College, Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712046, China;
2.Department of Urology, Xianyang Central Hospital, Shaanxi Province, Xianyang 712000, China
Abstract：Objective To evaluate the efficacy of simple bladder hydrodistention to treat female refractory overactive bladder. Methods Sixty-two female patients with refractory overactive bladder treated in Xianyang Central Hospital from February 2015 to August 2017 were selected and they were divided into simple bladder hydrodistention group (observation group) and Capsaicin (CAP) group (control group), with 31 cases in each group. OABSS scores, daily voiding frequency, urinary frequency in night, quantity of each urination, bladder capacity at first desire, maxima bladder capacity were recorded. Results OABSS scores, daily voiding frequency, urinary frequency in night, average quantity of each urination, bladder capacity at first desire, maxima bladder capacity after treatment in the two groups had difference with those before treatment （P ＜ 0.05）. One 1 week after treatment, urinary frequency in night, average quantity of each urination, bladder capacity at first desire, maxima bladder capacity in the observation group were different from those in the control group （P ＜ 0.05）. Three months treatment after, there were differences in daily voiding frequency and maxima bladder capacity between the two groups, the differences were statistically significant （P ＞ 0.05）. There was no significant difference in clinical treatment efficiency between the two groups (P ＞ 0.05). Conclusion Simple bladder hydrodistention can be used as a supplement treatment for refractory bladder overactivity.
[1] Hsiao SM，Liao CH，Lin HH，et al. Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy：An Analysis of Predictive Factors [J]. Int Neurourol J，2015，19（3）：171-177.
[2] Lai HH，Shen B，Rawal A，et al. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population [J]. Bmc Urology，2016，16（1）：60.
[3] Corcos J，Przydacz M，Campeau L，et al. Appendix：Executive summary of CUA guideline on adult overactive bladder [J]. Can Urol Assoc J，2017，11（5）：E248-E249.
[4] Kosilov KV，Loparev S，Kuzina I，et al. Comparison of objective and subjective factors in the adherence to antimuscarinics when treating overactive bladder in employed persons [J]. Ther Adv Urol，2017，9（12）：271-279.
[5] Schwantes U，Grosse J，Wiedemann A. Refractory overactive bladder: a common problem? [J]. Int Urogynecol J，2015，26（10）：1407-1414.
[6] Wang CC，Jiang YH，Kuo HC. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder [J]. Low Urin Tract Symptoms，2017，9（1）：27-32.
[7] Tyagi P，Kashyap M，Yoshimura N，et al. Past，present，and future of chemodenervation with botulinum toxin in the treatment of OAB [J]. J Urol，2017，197（4）：982-990.
[8] Zhu T，Feng XJ，Zhou Y，et al. Therapeutic effects of electrical stimulation on overactive bladder：a meta-analysis [J]. Springerplus，2016，5（1）：2032.
[9] Harris S，Rizzolo D. Botulinum toxin as a treatment for refractory overactive bladder [J]. JAAPA，2016，29（2）：1-4.
[10] Hikita KS，Honda M，Hirano S，et al. Comparison of the overactive bladder symptom score and the overactive bladder symptom score derived from the bladder diaries [J]. Neurourol Urodyn，2016，35（3）：349-353.
[11] 史本康.膀胱过度活动症的诊断及治疗进展[J].山东大学学报：医学版，2018，56（3）：1-5.
[12] Chu FM，Dmochowski R. Pathophysiology of overactive bladder [J]. Ame J Med，2006，119（3 supply 1）：3-8.
[13] Wong J，Tincello DG. Management of refractory overactive bladder [J]. Obstetrician & Gynaecologist，2016（18）：173-181.
[14] Guzmannegron JM，Goldman HB. New Devices and Technologies for the Management of Overactive Bladder [J]. Curr Urol Rep，2017，18（12）：94.
[15] Ginsberg DA. OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder：Pro [J]. J Urol，2017，197（1）：11-13.
[16] Dowson C，Watkins J，Khan MS，et al. Repeated botulinum toxin type A injections for refractory overactive bladder：medium-term outcomes，safety profile，and discontinuation rates [J]. Eur Urol，2012，61（4）：834-839.
[17] Cruz F. Mechanisms involved in new therapies for overactive bladder [J]. Urology，2004，63（3 supply 1）：65-73.
[18] Chayaprasithi B. Over Overactive Bladder（OAB）[J]. Siriraj Medical Journal，2017，59（5）：255-258.
[19] Keay S，Kleinberg MC，Hise M，et al. Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production [J]. J Urol，2000，164（6）：2112-2118.
[20] Parsons CL，Zupkas P，Proctor J，et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis [J]. J Sex Med，2012，9（1）：207-212.
2018, Vol. 15 
京公网安备 11010502046598号